IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
03. August 2023 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
29. September 2022 17:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
15. September 2022 08:30 ET
|
Celsion Corporation
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE)...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
19. Juli 2022 08:30 ET
|
Celsion Corporation
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08. April 2022 16:30 ET
|
Celsion Corporation
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct...
Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update
15. November 2021 08:30 ET
|
Celsion CORP
Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE...
Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021
09. November 2021 09:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses
08. November 2021 09:00 ET
|
Celsion CORP
Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised...
Celsion to Present at Three Investment Conferences in October
30. September 2021 09:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
12. August 2021 08:00 ET
|
Celsion CORP
Strong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine InitiativeConference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 12,...